Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab and Bevacizumab plus Chemotherapy in Advanced cHCC-CC
NCT05211323Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Dec 2022
- Primary completion
- Jan 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in Combined hepatocellular-cholangiocarcinoma (cHCC-CCA), sponsored by National Cancer Institute. Started Dec 2022; status: active, not recruiting.
02
Drugs
bevacizumab
03
Conditions
Combined hepatocellular-cholangiocarcinoma (cHCC-CCA)
Beyond the preview
Go deeper on NCT05211323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05211323.